Thank you for the transfer of your manuscript to our journal. We have now received the comments from the referees, as well as referee cross-comments, which are pasted below.
manuscript will depend on a positive outcome of a second round of review. It is EMBO reports policy to allow a single round of revision only and acceptance or rejection of the manuscript will therefore depend on the completeness of your responses included in the next, final version of the manuscript.
Regarding data quantification, please specify the number "n" for how many experiments were performed, the bars and error bars (e.g. SEM, SD) and the test used to calculate p-values in the respective figure legends. This information is currently incomplete and must be provided in the figure legends. Please also include scale bars in all microscopy images.
We now strongly encourage the publication of original source data with the aim of making primary data more accessible and transparent to the reader. The source data will be published in a separate source data file online along with the accepted manuscript and will be linked to the relevant figure.
If you would like to use this opportunity, please submit the source data (for example scans of entire gels or blots, data points of graphs in an excel sheet, additional images, etc.) of your key experiments together with the revised manuscript. Please include size markers for scans of entire gels, label the scans with figure and panel number, and send one PDF file per figure or per figure panel.
I look forward to seeing a revised version of your manuscript when it is ready. Please let me know if you have questions or comments regarding the revision.
REFEREE REPORTS
Referee #1:
In the manuscript 'Loss of CHD1 confers DNA repair defects and alters prostate cancer therapeutic responsiveness' Kari et al. investigate the role of CHD1 in the DNA damage response. From their experiments the authors conclude that CHD1 plays a role in the repair of DNA double strand breaks (DSBs) by homologous recombination (HR). In their model, CHD1 helps to open up chromatin around sites of DNA damage, promoting the early DNA end resection step of HR through facilitating the recruitment of CtIP. This model is consistent with the strong hypersensitivity to olaparib that the authors observe for CHD1-depleted cells when using olaparib as a stand-alone agent or in combination with ionizing radiation. Strikingly, CHD1 is mutated or deleted in a high percentage of prostate cancers. Thus, the results of this study could in the future contribute to the stratification of prostate cancer patients based on the cancer's CHD1 status.
The olaparib data in this study are strong and convincing. Moreover, they are in line with the role that the authors are proposing for CHD1 in DSB repair, which is novel and interesting to a broad readership. However, the experimental evidence to support the authors' conclusions regarding the mechanistic role of CHD1 in HR are far from sufficient. Therefore, I cannot support this manuscript for publication in EMBO Reports at this stage.
The authors would have to thoroughly address the following major points to strengthen their hypothesis:
1. Recruitment of CHD1 to sites of DNA damage: the pan-nuclear staining of CHD1 (see especially Fig. S1A ) makes it impossible to judge whether CHD1 is actually recruited to DNA damage foci. This also holds true for the PLAs in Figure 1D . Due to CHD1's global presence along chromatin, CHD1 is expected to show a positive signal at gammaH2AX-positive sites, even if it is not specifically recruited to sites of DNA damage. Moreover, the representative image used to show recruitment of CHD1 to I-SceI-induced DSBs marked by GFP-lacR (Fig. 1B) , is not convincing: it appears that doxycycline-mediated induction of I-SceI expression results in generation of the high background levels of DNA damage as the nucleus is full of gammaH2AX staining. I-SceI should specifically induce a DSB at the recognition site. These issues could and should potentially be resolved by performing laser micro-irradiation studies for CHD1. The latter assay would be more sensitive and might allow the authors to unequivocally detect CHD1 accumulation at sites of DNA damage even over a high pan-nuclear CHD1 background.
2. Delayed DNA damage repair in CHD1-depleted cells: the effects on gammaH2AX appear rather minor in the IF analyses ( Fig. 2A-C ), but fairly strong by Western blot (Fig. 2C) . It is usually the other way around due to the higher sensitivity of the IF over immunoblot assays. Can the authors explain this discrepancy? Also, it seems that the authors base their conclusions on one mix of siRNA oligos targeting CHD1. It is essential to deconvolute this mix and demonstrate that independent siRNAs lead to the same effects in various assays that are key to this study e.g. HR assay, DNA repair defects etc.
3. General recruitment of CHD1 to chromatin in response to DNA damage: the chromatin fractionation studies in Figures 1E, S1D and S1E support the idea of CHD1 accumulation on chromatin following DSB induction. However, in Figure 2C , the levels of CHD1 seem to increase after treatment with NCS, especially at the 24 h time point. Thus the question is whether CHD1 accumulation on chromatin following DNA damage treatment is due to its specific recruitment or merely a consequence of increased expression of CHD1 after DNA damage?
4. HR/NHEJ assays: the dynamic range is very low for the assays (plus the comprehensive labeling of the y axes is missing in Figures 3A-B) . Did the authors normalize for I-SceI transfection efficiencies? In addition, when describing the kinetics of RAD51 focus formation and disappearance ( Figure 3D ), the authors state that the reduced number of RAD51 foci in CHD1-depleted cells at the 3h time point strongly suggests the role for CHD1 in the early stage of HR, namely DNA-end resection. To confirm that this is indeed the case, the authors should perform assays that would directly assess the extent of DNA-end resection in CHD1-depleted cells. The most convincing would be either high-throughput IF-or FACS-based assays to quantify RPA or BrDU signal in gammaH2AX-positive/cyclin A-positive cells following DNA damage induction. The data on RPA reduction in Figure 4D is not sufficient both due to the nature of the LacR assay and due to the problems with these particular data mentioned below (see point 5). With regard to Figure 3D , it is also striking that 24h after damage, RAD51 foci persist in CHD1-depleted cells. This could mean that CHD1 plays a role at the later stage of HR. Such observations deserve more attention. Figure 4A is not conclusive due to the pan-nuclear and chromatinbound nature of CHD1 and also due to the known difficulties in visualizing CtIP foci after IR. To resolve this ambiguity, the authors would have to perform laser-microirradiation studies and check for CtIP recruitment specifically in S/G2-phase cells, as CtIP is not recruited to DSBs in G1 phase. In this regard, it is surprising that the authors detect CtIP-positive foci in 100% of the control cells in Figure 4C . The same goes to RPA foci in Figure 4D . One would expect the percentage to correlate with the percentage of cells in S/G2 phase. These are important issues that the authors need to address.
CtIP recruitment: the PLA in
6. CHD1 complementation: The assay in Figure 4E is confusing. What are the pan-nuclear signals? This is difficult to explain, as gammaH2AX would be expected to show foci and not pan-nuclear staining, in all conditions tested.
7. The role for MRE11 in CHD1 recruitment: the results in Figure 5A are surprising and the blot is not convincing overall. Why do the CHD1 and CtIP signals go down at 4 and 6 hours in the mirintreated cells while the signals are really high at 2h? To test if there are any MRE11-dependent effects, this experiment should also be performed with siRNAs targeting MRE11. Moreover, it looks like the membranes for gammaH2AX are spliced together for the three 4-time-point conditions. This should be clearly indicated.
Referee #2:
This study by Kari et al seeks to address the role of CHD1 in DNA double strand breaks in prostate cancer cells. The paper provide direct evidence that CHD1 is recruited to DSBs and is necessary for end resection, its depletion in combination with DSBs subsequently leads to reduced CtIP and RPA recruitment to DSBs and reduced RAD51 foci and sustained yH2AX levels. Thus CHD1 is important for HR but not NHEJ, and prostate cancer cells depleted of CHD1 show increased sensitivity to PARP inhibition. Thus, the authors show that they have identified a synthetic lethal relationship between CHD1-deficiency and PARP inhibition. In light of the usage of PARP inhibitors in treatment of castration defective prostate cancers these data are extremely important as it could indicate that the CHD1 mutated cancers respond to PARP inhibitors.
It has previously been shown by Boulton et al 2009, Science, that the CHD1L (also called ALC1) that shows substantial sequence similarity to CHD1 is targeted to sites of DNA damage through interaction with poly(ADP-ribose) and functions to regulate chromatin during DNA repair. It is able to catalyze nucleosome sliding in an ATP-dependent manner and its helicase activity is strongly stimulated upon poly(ADP-ribose)-binding. Thus the findings the authors provide that CHD1 has a similar role as CHD1L in HR is not totally surprising. Yet the authors do not discuss their findings in relation to this reference or investigate the potential overlapping roles of CHD1L and CHD1 in PARP dependent recruitment of factors for chromatin relaxation in HR.
The majority of the experiments in the paper are done using shCDH1 but the authors seem to have used only one hairpin targeting CDH1, the authors should perform the same experiments with at least one more shRNA targeting CHD1 to exclude that the results are not due to unspecific off-target effects by the hairpins. For the siRNA, four different siRNA sequences are shown in the supplementary table but only one seems to have been used in the figures. The authors should specify which one of the four CDH1 siRNAs that has been used the figures, or if a mix of the siRNAs have been used, as well as show the effects on the individual siRNAs on CDH1 protein and mRNA level. The authors should repeat some experiments using 2 different siRNAs targeting CDH1 to avoid that results are due to unspecific off-target effects by the siRNAs. In many cases there is also a lack of information regarding how many times experiments have been repeated, sometimes representative confocal images of one nuclei per treatment is shown without any quantifications, and it is therefore unclear if some of the data is reproducible.
The authors should discuss the potential overlapping roles of CHD1L and CHD1 in PARP dependent recruitment of factors for chromatin relaxation in HR. The recruitment of CHD1 to strand breaks should be characterized in more detail, e.g. look at kinetics for CHD1 recruitment to breaks as well as colocalization with yH2AX upon microirradiation. The impairment of the DNA damage response induced by CHD1-depletion upon should be investigated in more detail (e.g. look checkpoint activation and cell cycle progression). Figure S1 A: Reference to this figure is missing in the main text. The authors claim that CHD1 and yH2AX interact using the PLA assay. It would be helpful for the readers if the authors could quantify the interaction of yH2AX/CHD1 in NCS treated and non-treated cells as it is hard to draw conclusions regarding interaction upon DSB-induction from a representative image of one nuclei per treatment. Figure S1 C: Similar to Figure S1 A, please quantify the interaction detected in the PLA assays and provide information on how many cells that were quantified per condition. Figure 2A : The text in the results sections states that the irradiation was 2 Gy but the figure legend states 3 Gy, which dose was used? 8) Figure 2C : The authors should complement the NCS treatment to look at prolonged yH2AX signaling on western blot with irradiation, as done in the rest of the panels in the figure which investigate sensitivity to ionizing radiation upon CDH1 depletion. Figure 2 , the authors show prolonged yH2AX activation upon CHD1 depletion in combination with irradiation, the author should complement this data with investigating checkpoint signaling and cell cycle progression. 10) Figure 2D : P-values are missing for the colony formation assays. Figure 4A : It would be helpful for the readers if the authors could quantify the interaction between CtIP and CDH1 in the PLA assay with and without induction of DSBs with NCS to be able to compare the effects on DSBs on the interaction. 12) Figure 4B and S3A and B: The authors claim that CtIP does not increase over time in CHD1 depleted cells, however it is absent at early (2h) timepoint but increase over time in Fig. 4B Figure 5C : Please also clearly mark which bars are siCDH1. Figure 5D showed be moved out as a separate figure as it at the moment is not referred to in the result section and is described after figure 6. Figure 6A , 6C 6D ands S5A: P-values are missing for the colony formation assays. The authors should also acknowledge the difference in response between the two cell lines.
6)

7)
9) In
11)
19)
20)
21)
22) Reference to figure 6F is missing. figure 2D is not impressive, the survival data when combining shCDH1 with Olaparib in figure 6C and D are striking. As PARP is known to As the authors connect the decrease in chromatin opening upon CHD1 depletion with the decreased HR activity and cell survival upon siCHD1 it would be most interesting if the authors could investigate how combination of siCHD1 and Olaparib affects chromatin opening at DSB sites employing the FAIRE assay.
23) Although the survival data in
Referee #3:
This manuscript from Kari et al deals with a new role of the chromatin remodeller CHD1 in homology-directed recombination (HDR). The authors find that CHD1 is recruited to DNA double strand break sites, and that CHD1 depletion decreases the recruitment of the key DNA end resection protein CtIP to chromatin. Hence, CHD1 depleted cells display impaired end resection during DNA double strand break repair and HDR is reduced. CHD1 is frequently deleted in prostate cancer, correlating with poor prognosis, and the authors now find that PARP1 inhibition eradicates CHD1-depleted cells. PARP1 inhibition is efficient in eliminating HDR deficient cancers, thus, the authors identify a potential therapeutic possibility for targeting CHD1-deleted tumours through PARP1i.
Major comments: This is clearly a work of interest to several fields due to the identification of a new role of CHD1 in HDR that links chromatin remodeling, DNA repair and cancer. The manuscript is well written, and experiments are generally well executed and controlled.
Minor comments: *The resection phenotype as detected by the RPA staining is not very apparent (4D), yet, it is a key point in this study. The authors should address this aspect in more detail by a more complete ssDNA analysis (RPA staining and non-denatured BrdU staining after high-dose IR, such as 10 Gy 2h). *To generalise the findings, normal (non-transformed cell lines) should be assayed for CHD1 impact on DNA end resection. *A recent publication identified SRCAP as an important chromatin remodeller in CtIP driven resection, this should be discussed and referenced, PMID: 25176633 . *The impact of CHD1 status on yH2AX levels is modest and yH2AX is an indirect damage marker. The authors should detect actual DNA damage after CHD1 depletion by a more direct approach (Neutral comet or PFGE).
Cross-comments from Referee 3:
In general, the reviewers comments are of course highly relevant and useful, their inclusion will clearly lead to a much improved manuscript. However, I do find that a few of the points/suggestions are too demanding relative to the scope of the manuscript. In particular:
*Rev #1, Point 5: The laser-microirradiation experiments for CtIP are very demanding and far from straightforward (the temporal CtIP recruitment pattern is complex, laser irradiation is not equivalent to IR/NCS treatment, CtIP expression levels affect its behaviour). However, I do agree that the manuscript will be strengthened by improved analysis of CtIP recruitment. Perhaps the authors can improve the quality of data with their current approach, including analysis of CtIP foci formation upon IR/NCS in different cell cycle phases (based on cell cycle markers or synchronization of cells). *Rev#2, Point 9: The scope of the manuscript is clearly on DNA repair aspects, I really find the checkpoint aspect of minor importance. *Rev #2, Point 16: Although the potential kinase mediated regulation of CHD1 recruitment is of interest and relevance, I also do not find this of major importance. This line of research would require a much more dedicated analysis with kinase targeting siRNA and perhaps CHD1 mutants to really improve the manus significantly. *Rev #2, Point 23: In the context of the manuscript, this is not an important point. We kindly thank you and the reviewers for your enthusiasm for our manuscript and your helpful comments and suggestions. In the revised manuscript we have sought to address each of the reviewer's concerns to the best of our ability. Below you will find a point-to-point response to each critique.
I hope that you will find this revised version of the manuscript suitable for publication. If you have any questions or require any additional information, please feel free to contact me again.
We thank the reviewer for pointing out the oversight of having left of the labeling. We have now included the labeling in the y-axis. Indeed, all HR and NHEJ assays were normalized to the transfection efficiency of I-SceI vector.
In addition, when describing the kinetics of RAD51 focus formation and disappearance ( Figure 3D ), the authors state that the reduced number of RAD51 foci in CHD1-depleted cells at the 3h time point strongly suggests the role for CHD1 in the early stage of HR, namely DNA-end resection. To confirm that this is indeed the case, the authors should perform assays that would directly assess the extent of DNA-end resection in CHD1-depleted cells. The most convincing would be either highthroughput IF-or FACS-based assays to quantify RPA or BrDU signal in gammaH2AX-positive/cyclin A-positive cells following DNA damage induction. The data on RPA reduction in Figure 4D is not sufficient both due to the nature of the LacR assay and due to the problems with these particular data mentioned below (see point 5). With regard to Figure 3D , it is also striking that 24h after damage, RAD51 foci persist in CHD1-depleted cells. This could mean that CHD1 plays a role at the later stage of HR. Such observations deserve more attention.
In order to address the reviewer's concern regarding the CHD1 role in DNA-end resection process we performed the native BrdU assay in control and siCHD1 transfected cells 2 h after NCS treatment. Our results show that depletion of CHD1 in PC3 cells results in decreased DNA-end resection as further indicated by decreased BrdU staining after NCS treatment (Fig. 5E and EV5J). To further assess the role of CHD1 in RPA1 recruitment we performed IF studies for RPA1 and CenpF (an established marker for S/G2) with PC3 cells depleted with siCHD1 (four individual siRNAs). As now shown in Fig. EV4J-K, CHD1 depletion reduced the RPA1 foci formation more specifically in S/G2-phase of cells, further confirming a role for CHD1 in HR-mediated DSB repair. Depletion of CtIP was used as a positive control.
5. CtIP recruitment: the PLA in Figure 4A is not conclusive due to the pan-nuclear and chromatinbound nature of CHD1 and also due to the known difficulties in visualizing CtIP foci after IR. To resolve this ambiguity, the authors would have to perform laser-microirradiation studies and check for CtIP recruitment specifically in S/G2-phase cells, as CtIP is not recruited to DSBs in G1 phase.
Cross-comment from Referee 3: *Rev #1, Point 5: The laser-microirradiation experiments for CtIP are very demanding and far from straightforward (the temporal CtIP recruitment pattern is complex, laser irradiation is not equivalent to IR/NCS treatment, CtIP expression levels affect its behaviour). However, I do agree that the manuscript will be strengthened by improved analysis of CtIP recruitment. Perhaps the authors can improve the quality of data with their current approach, including analysis of CtIP foci formation upon IR/NCS in different cell cycle phases (based on cell cycle markers or synchronization of cells).
In order to address the phase specific recruitment of CtIP and its regulation by CHD1, we performed immunofluorescence analyses for CtIP and CenpF 2 h after irradiation in cells transfected with CHD1 depletion using siRNA (four individual siRNAs) in PC3 cells. The results clearly indicate that CHD1 depletion decreased CtIP focus formation specifically in S/G2-phase cells. This is shown in Fig. EV4H-I.
In this regard, it is surprising that the authors detect CtIP-positive foci in 100% of the control cells in Figure 4C . The same goes to RPA foci in Figure 4D . One would expect the percentage to correlate with the percentage of cells in S/G2 phase. These are important issues that the authors need to address.
In Fig.4C (Fig. 5A ).
Moreover, it looks like the membranes for gammaH2AX are spliced together for the three 4-timepoint conditions. This should be clearly indicated.
Below is the original blot for the γH2AX where the loading order is different compared to the other blots. For this reason the blot was cut in order to place the blots above one another.
Referee #2: 1) Figure 1 B, C. The authors claim that CHD1 localizes to DNA double strand breaks and colocalizes with yH2AX, quantification is shown in C. However, the number of cells used per condition for the quantification in C) is missing.
We have now included the number of cells used per condition for the quantification in the figure legend.
2) Figure 1 D: It would be helpful for the readers if the authors could quantify the co-localization if yH2AX/CHD1 in Edu positive and negative cells as it is hard to draw conclusions from a set of representative images.
We have now included the quantification of the co-localization of γH2AX/CHD1 in EdU positive and negative cells from control and NCS treated cells (Fig.1E ).
3) Figure figure S1D , E?
We thank the reviewer for pointing out this oversight. We have now included the label in the Fig.1F (which is NCS). Figure S1 A: Reference to this figure is missing in the main text.
5)
We have included the reference for Fig.S1A in the text.
The authors claim that CHD1 and yH2AX interact using the PLA assay. It would be helpful for the readers if the authors could quantify the interaction of yH2AX/CHD1 in NCS treated and nontreated cells as it is hard to draw conclusions regarding interaction upon DSB-induction from a representative image of one nuclei per treatment. 6) Figure S1 C: Similar to Figure S1 A, please quantify the interaction detected in the PLA assays and provide information on how many cells that were quantified per condition. Fig. S1C is from the PLA assay to check the co-localization of γH2AX/CHD1 upon DNA DSB induction. Further to check the specificity of this interaction we depleted CHD1 using siRNA, the depletion of CHD1 completely abolished the PLA signal. The data is similar to the data represented in Fig. 1D Fig. 1E . Figure 2A : The text in the results sections states that the irradiation was 2 Gy but the figure legend states 3 Gy, which dose was used?
The data represented in
7)
We thank the reviewer for pointing this out and have now corrected the text and mention the exact dose (3 Gy) used for the experiment.
8) Figure 2C : The authors should complement the NCS treatment to look at prolonged yH2AX signaling on western blot with irradiation, as done in the rest of the panels in the figure which investigate sensitivity to ionizing radiation upon CDH1 depletion. Figure 2 , the authors show prolonged yH2AX activation upon CHD1 depletion in combination with irradiation, the author should complement this data with investigating checkpoint signaling and cell cycle progression. 10) Figure 2D : P-values are missing for the colony formation assays.
Please see also comment # 3 from Reviewer 1. As the reviewer has suggested, we have repeated the experiment with irradiation and analyzed for γH2AX and CHD1 levels (Fig. 2C is now replaced with new data).
9) In
Cross-comment from
We have now included p-valves for the colony formation assays
11) Figure 4A : It would be helpful for the readers if the authors could quantify the interaction between CtIP and CDH1 in the PLA assay with and without induction of DSBs with NCS to be able to compare the effects on DSBs on the interaction.
We have now included the quantification of PLA signal for CHD1/CtIP from PLA assay in Fig. 4A and represented the data in a graph in Fig. S4A . Figure 4B and S3A and B: The authors claim that CtIP does not increase over time in CHD1 depleted cells, however it is absent at early (2h) timepoint but increase over time in Fig. 4B (PC3 cells). The authors should acknowledge the difference in CtIP recruitment to chromatin between cell lines (VcAP S3A, U-2 OS S3B and PC3 Fig4B). Figure 4C and D showed be moved to be under panel A and B and panel E should be where panel C and D currently are. Fig.4. 14) It is unclear if the quantification in Figure 4 is from the chromatin fractionations in S3H?
12)
As the reviewer has suggested, a statement has been added to the description of the figures stating that the kinetics of recruitment varied slightly between the cell lines. We have not specifically added a statement regarding the 2 h time point since this apparent absence is not seen in the other cell systems and is probably not representative of general mechanisms.
13)
As reviewer suggested we have now rearranged the panels in
The graph which represented Figure 4F , is the quantification form the Western blot data from the rescue experiment which was shown in S3H (now Fig. EV4O ). Figure 4E : The authors claim a decreased PLA signal in panel E upon CDH1 depletion and this can be rescued by WT but not mutant CDH1, as this is difficult to interpret from the images the authors should include quantifications of the PLA signals in the figure.
15)
We have quantified the PLA single from Fig. 4E and represented these in a graph (Fig. EV4M) 
as a fraction of cells containing punctate staining from all the cells as well as the percentage of cells which contain HA signal (i.e, those transfected with the respective expression vectors).
Also, this panel is without NCS treatment/induction of DSBs and the authors should investigate if CDH1 depletion also affect DSB-induced interaction between yH2AX and CHD1.
The specificity of PLA signal and the interaction between γH2AX/CHD1 was confirmed by CHD1 depletion followed PLA assay for γH2AX/CHD1, which is was shown in Fig. EV1C . The depletion of CHD1 completely abolished the PLA signal which shows the specificity of interaction between γH2AX/CHD1. Figure 5A : The authors show that inhibition of PARP does not affect CHD1 recruitment to chromatin upon induction of DSBs. To further characterize the signaling pathways and show that the CHD1 is involved in HR pathway and not NHEJ the authors should compare CHD1 recruitment upon ATM, ATR and DNA-PK inhibition in combination with NCS treatment. Figure S2B ,C: P-values are missing for the colony formation assays.
16)
Cross-comment from
18)
We have now included p-values for figures EV2B and C.
19) Figure 5C : Please also clearly mark which bars are siCDH1.
We have now mentioned the bars as siCHD1 in Fig. 5C (now 5D) 20) Figure 5D showed be moved out as a separate figure as it at the moment is not referred to in the result section and is described after figure 6 . Figure 6A , 6C 6D and S5A: P-values are missing for the colony formation assays. The authors should also acknowledge the difference in response between the two cell lines.
Indeed, we agree with the reviewer's comment and have moved the model to Figure 6 (6G).
21)
As suggested by the reviewer, we have now included the p-values for the data represented in the figures.
22) Reference to figure 6F is missing.
We thank the reviewer for pointing out this oversight and have now appropriately referenced Fig.  6F in the text. figure 2D is not impressive, the survival data when combining shCDH1 with Olaparib in figure 6C and D are striking. As PARP is known to As the authors connect the decrease in chromatin opening upon CHD1 depletion with the decreased HR activity and cell survival upon siCHD1 it would be most interesting if the authors could investigate how combination of siCHD1 and Olaparib affects chromatin opening at DSB sites employing the FAIRE assay. Referee #3:
23) Although the survival data in
Cross-comment from
Minor comments:
*The resection phenotype as detected by the RPA staining is not very apparent (4D), yet, it is a key point in this study. The authors should address this aspect in more detail by a more complete ssDNA analysis (RPA staining and non-denatured BrdU staining after high-dose IR, such as 10 Gy 2h). (Fig. 5E, S5J ).
Please see also comment # 4 from reviewer 1. Briefly, we have performed native BrdU assay in PC3 cells in mock and siCHD1 depleted cells after 2 h of NCS treatment
*To generalise the findings, normal (non-transformed cell lines) should be assayed for CHD1 impact on DNA end resection.
While we agree that it may be interesting to study the impact of CHD1 on non-transformed cells, the models available for normal prostate epithelial cells are very limited. Thus, as cross commented by the editor, we could not address this in a timely manner in the current study.
*A recent publication identified SRCAP as an important chromatin remodeller in CtIP driven resection, this should be discussed and referenced, PMID: 25176633.
Indeed, the authors agree that this is an interesting paper which shows the importance of chromatin remodelers during the end resection process.
We have included the reference in our discussion. 
DSB-II
0 h 6 h *The impact of CHD1 status on yH2AX levels is modest and yH2AX is an indirect damage marker. The authors should detect actual DNA damage after CHD1 depletion by a more direct approach (Neutral comet or PFGE). Fig. EV2A-B and indicate that loss of CHD1, indeed, leads to defects in DNA repair.
To address this we have performed neutral comet assay in control and CHD1-depleted cells upon NCS treatment for 30 min and 6h. The data are shown in
Cross-comments from Referee 3:
We kindly thank the referee for their helpful insights and suggestions.
2nd Editorial Decision 14 July 2016
Thank you for the submission of your revised manuscript to our journal. We have now received comments from all three referees, as well as cross-comments, that are pasted below.
As you will see, while referee 1 is more critical, both referees 2 and 3 support the publication of your revised study, despite referee 3's concerns. However, the remaining concerns need to be clearly addressed in the manuscript text, i.e. overstatements regarding Chd1 recruitment to DSB must be avoided, blot quality must be improved, and all information on materials and methods must be included.
Please specify the number "n" for how many experiments were performed, the bars and error bars and the tests used to calculate p-values for Figure 1C , 2B, 3A, 3D, 4F, 6A-D, EV3, EV4, EV5. If the information is the same for all figure panels, a single sentence at the end of the legend is sufficient. Please also add scale bars to all microscopy images.
In figure 2C the second row of bands has a very different background. Are all bands derived from the same gel/blot? Please send us the source data with the full gels to show where the bands come from. Please also leave some white space around all spliced bands in order not to give the impression that the figure panel is one piece of gel.
Please change figure 3 into portrait format, as we cannot layout figures in landscape format.
In figure EV1 the top right image of the bottom panel seems to be empty. Some background staining of the cell should be visible. Please explain what happened and send us a new figure with the primary data.
In figure EV2 the bottom middle panel has a nmber of horizontal lines on it. Can you please explain what this is?
I would also like to suggest some changes to the manuscript title and abstract:
Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness
The CHD1 gene, encoding the Chromo-domain Helicase DNA-binding protein-1, is one of the most frequently deleted genes in prostate cancer. Here we examine the role of CHD1 in DNA double strand break (DSB) repair in prostate cancer cells. We show that CHD1 is required for the recruitment of CtIP to chromatin and subsequent end resection during DNA DSB repair. Our data support a role for CHD1 in opening the chromatin around the DSB to facilitate the recruitment of homologous recombination proteins. Consequently, depletion of CHD1 specifically affects homologous recombination (HR)-mediated DNA repair but not non-homologous end joining. Together, we provide evidence for a previously unknown role of CHD1 in DNA DSB repair via HR, and show that CHD1 depletion sensitizes cells to olaparib and PARP inhbitors, which has potential therapeutic relevance. Our findings suggest that CHD1 deletion, like BRCA1/2 mutation in ovarian cancer, may serve as a marker for prostate cancer patient stratification and the utilization of targeted therapies such as PARP inhibitors, which specifically target tumors with HR defects.
Please let me know whether you agree with these changes.
I am looking forward to receiving a final version of your manuscript as soon as possible. Let me know please if you have any questions.
REFEREE REPORTS
The revised manuscript by Kari et al. is definitely improved over the original submission. However, there remain issues with this study, including lack of mechanistic insight, that prevent me from recommending this work for publication in EMBO Reports.
1. Lack of convincing demonstration of CHD1 DSB recruitment still remains a key issue: -The argument in the rebuttal letter that CHD1 distribution across genome is not random and that it associates with a subset of gene promoters and enhancers does not mean that CHD1 localises to the sites of DNA damage.
-The very high background staining of γH2AX upon doxycycline-mediated induction of I-SceI expression (Fig. 1B) can't be due to the I-SceI cutting at "endogenous" sites as the authors suggest in the rebuttal letter: there are no endogenous I-SceI sites in either human or murine genomes.
-The PLA assays are not at all informative due to the fact that CHD1 is evenly chromatin bound before and after DSB induction and therefore some of it will co-localize with γH2AX. Moreover, as CHD1 accumulates on chromatin upon damage (these data are very strong), the PLA signal is expected to increase. Overall, this reviewer is not convinced by the conclusions that the authors draw from the PLA data.
2. In Fig. 2C , persistence of γH2AX signal upon CHD1 depletion was previously demonstrated by the immunoblot following treatment of cells with NCS. In the revised manuscript, this has been replaced with the immunoblot following IR, which is the same treatment as used in IF data in Fig.  2A . Unfortunately, the new blot is of very poor quality and, interestingly, over time the levels of CHD1 in siCont go up after NCS (old Fig.2C ) and down after IR (new Fig. 2C ).
3. In the previous version of Figs. 4C and 4D, the proportion of cells with either CtIP or RPA foci, respectively, was presented as 100% in control cells. As the authors explain in the rebuttal letter, those were normalized values and that in the revised manuscript, the actual percentages are now plotted. The concern however is that in the former version the difference between siCont and siCHD1 was about 5-fold for CtIP foci (from 100 to 20%) and now it is approximately 2.5 fold (from 17 to 7%). Isn't it expected that upon normalization the relative differences should remain the same? It is also somewhat surprising that the fraction of CtIP and RPA focus forming cells is only 20-25% because usually, the proportion of S/G2 cells in U2OS culture is about 2-2.5 fold higher. However, the reviewer accepts that the latter might be due to the nature of the particular assay.
4. As suggested by the reviewers, the authors performed experiments to address the role of CHD1 in DNA end-resection. However, the data in the main Fig. 5E do not allow fair judgement of the effect CHD1 has on resection as it's an image of a single cell. The quantitative data in Fig. EV4 is far more informative. The reviewer is still mystified though how the authors manage to detect clear multiple foci of endogenous CtIP following the 2Gy dose, as others in the field are not able to do this.
As a general comment, the authors don't seem to include information on the antibodies used in the study.
Referee #2:
The authors have properly addressed all concerns Referee #3:
The Authors have adequately addressed my points and I support its publication in EMBO Reports.
Referee Cross-comments:
Referee 1:
As I was the harshest of the reviewers, I have softened my review. I would be happy for this work to be published if the authors can address the following points:
• Make at least some statement about the ISCe1 data being surprising as there are reportedly no endogenous sites.
• Point 3; they explain how their data were quantified and normalised compared to the previous data.
• Point 4: they include the quantitative data in the main figure.
Referee 2:
I remain saying this is an important study and the overall conclusion well supported. I disagree that recruitment of CHD1 to DSB is important, the role in HR more important and of clinical relevance.
Referee 3:
Reviewer 1 is clearly far more critical of the study than I am; indeed the points are relevant, but I don't find that they should preclude publication of the manuscript. We kindly thank you, the other editors and the reviewers for your support and suggestions to further improve the manuscript. As suggested, in the second version of the revised manuscript we have now avoided overstating the recruitment of CHD1 to DSB sites. We have also included the changes in the title and the abstract as suggested (with one exception related to the redundancy of Olaparib an PARP inhibitors).
Below is a list of the suggested changes and how these have been addressed in the new version of the manuscript. Figure 1C We have now included the "n" number, p-vlaues and the method to calculate the significance in the figure legends (at the end). The scale bars for the microscopy images are added to the images.
Editorial comments
1.Please specify the number "n" for how many experiments were performed, the bars and error bars and the tests used to calculate p-values for
2. In figure 2C the second row of bands has a very different background. Are all bands derived from the same gel/blot? Please send us the source data with the full gels to show where the bands come from. Please also leave some white space around all spliced bands in order not to give the impression that the figure panel is one piece of gel.
In Fig. 2C , indeed the bands are derived from the same gel. We have how re-done these blots and have also provided the source data as to where the bands come from. As suggested by the editor we have now changed the figure with proper background and space around the spliced bands (as well as boxes around the bands of all blots to clearly delineate the edges of the cut regions).
3. Please change figure 3 into portrait format, as we cannot layout figures in landscape format.
We have now changed the Figure 3 into portrait format. We will also upload a PPT file which may potentially be of use for formatting the final version of the figures for publication.
4. In figure EV1 the top right image of the bottom panel seems to be empty. Some background staining of the cell should be visible. Please explain what happened and send us a new figure with the primary data.
In figure EV1C , the top right image of the bottom panel which shows the mock and CHD1 depleted cells without NCS treatment indeed appeared blank. We have now changed to contrast (in all the panels) to make sure that background is visible. We have also included the raw data. Reviewer 1 1. Lack of convincing demonstration of CHD1 DSB recruitment still remains a key issue: -The argument in the rebuttal letter that CHD1 distribution across genome is not random and that it associates with a subset of gene promoters and enhancers does not mean that CHD1 localises to the sites of DNA damage.
In the original concerns the reviewer implied that CHD1 is localized indiscriminately across the genome and that therefore a colocalization would not necessarily indicate sites of double-strand breaks. The point of our rebuttal was to state that CHD1 localization is highly specific across the genome. Thus, localization with sites of DNA damage (as shown by the PLAs) and the increased recruitment of CHD1 (i.e., via chromatin fractionation) are not simply due to non-specific localization of CHD1. If CHD1 were localized non-specifically across the genome (e.g., like core histone proteins), then a co-localization by PLA would not have any real meaning. On the other hand, since CHD1 is highly specifically localized to transcriptional start sites (mostly) and some enhancers (although we don't see much of this in our ChIP-seq data), the observed co-localization is most likely due to increased recruitment to DSB sites. Apart from this, in the case that CHD1 were already present at DSB sites, it would not diminish its mechanistic importance and necessity for DSB repair.
-The very high background staining of gH2AX upon doxycycline-mediated induction of I-SceI expression (Fig. 1B) can't be due to the I-SceI cutting at "endogenous" sites as the authors suggest in the rebuttal letter: there are no endogenous I-SceI sites in either human or murine genomes. We agree with the reviewers comment that there are no I-SceI endogenous sites in the human genome. Surprisingly we see that upon doxycycline treatment we observe that increased γH2AX signal, however, we have seen clearly observed that only in doxy treated cells CHD1 is co-localized with the lac array. We have now mentioned the background induction of γH2AX in doxy treated cells in the new version of the manuscript.
-The PLA assays are not at all informative due to the fact that CHD1 is evenly chromatin bound before and after DSB induction and therefore some of it will co-localize with gH2AX. Moreover, as CHD1 accumulates on chromatin upon damage (these data are very strong), the PLA signal is expected to increase. Overall, this reviewer is not convinced by the conclusions that the authors draw from the PLA data. Again, this is a point that the authors disagree with (see above). An even chromatin binding of CHD1 across the genome is not correct. We know (1) that CHD1 is localized to specific sites in the genome in untreated cells and (2) we know that there is increased recruitment of CHD1 following DNA damage (e.g., through chromatin fractionation studies).
2. In Fig. 2C , persistence of gH2AX signal upon CHD1 depletion was previously demonstrated by the immunoblot following treatment of cells with NCS. In the revised manuscript, this has been replaced with the immunoblot following IR, which is the same treatment as used in IF data in Fig. 2A . Unfortunately, the new blot is of very poor quality and, interestingly, over time the levels of CHD1 in siCont go up after NCS (old Fig.2C ) and down after IR (new Fig. 2C ). We agree with the reviewer's comment that the blot is not of a very good quality. This blot has been redone and included (together with source data) in the new version of the manuscript.
3. In the previous version of Figs. 4C and 4D, the proportion of cells with either CtIP or RPA foci, respectively, was presented as 100% in control cells. As the authors explain in the rebuttal letter, those were normalized values and that in the revised manuscript, the actual percentages are now plotted. The concern however is that in the former version the difference between siCont and siCHD1 was about 5-fold for CtIP foci (from 100 to 20%) and now it is approximately 2.5 fold (from 17 to 7%). Isn't it expected that upon normalization the relative differences should remain the same? It is also somewhat surprising that the fraction of CtIP and RPA focus forming cells is only 20-25% because usually, the proportion of S/G2 cells in U2OS culture is about 2-2.5 fold higher. However, the reviewer accepts that the latter might be due to the nature of the particular assay. For the revision the counts were performed again, thus the actual nuclei numbers and differences in absolute values can vary slightly from experiment to experiment. However, the significance and general effects clearly remain the same. Regarding the faction of CtIP and RPA foci with relation to S/G2 cells, the authors agree with the reviewer that due to the nature of the particular assay a direct relationship between S/G2 and cells with CtIP and RPA foci cannot be made in this case.
4. As suggested by the reviewers, the authors performed experiments to address the role of CHD1 in DNA end-resection. However, the data in the main Fig. 5E do not allow fair judgement of the effect CHD1 has on resection as it's an image of a single cell. The quantitative data in Fig. EV4 is far more informative. The reviewer is still mystified though how the authors manage to detect clear multiple foci of endogenous CtIP following the 2Gy dose, as others in the field are not able to do this. With regard to the end resection data, we have now included the quantitative data in the figure as well. Regarding the CtIP staining we agree that, it is difficult to obtain clear CtIP foci. In our hands the antibody seems to be a major determinant of the quality and reliability of the staining.
As a general comment, the authors don't seem to include information on the antibodies used in the study. Indeed, the supplemental information file was inadvertently forgotten in the last upload.
Additional comments from Referee 1: As I was the harshest of the reviewers, I have softened my review. I would be happy for this work to be published if the authors can address the following points:
• Make at least some statement about the ISCe1 data being surprising as there are reportedly no endogenous sites. As suggested by the reviewer and described above we have now included the statement in the manuscript about the back ground staining of γH2AX in doxy treated cells.
• Point 3; they explain how their data were quantified and normalized compared to the previous data.
We have now explained in the test how data were quantified and normalized in the text.
As suggested by the reviewers we have now included the quantification for Fig. 5E in the main figure as Fig. 5F We hope that these additional changes address all concerns and qualify the manuscript for publication in EMBO reports. We again thank you for your excellent suggestions and support and look forward to working together with you again in the future. Thank you for the submission of your revised manuscript to our editorial offices, which is now suitable for publication in EMBO reports. However, before we can proceed with the formal acceptance of your manuscript, I would like to ask you for some further minor revisions.
Could you please go through all the panels (including those indicated by my colleague in her decision letter) and add the relevant statistical testing and the information regarding this to the figure legends where these are still missing (the number "n" for how many experiments were performed, the bars and error bars and the test used to calculate p-values, and the value of the p-values). In the present version of the manuscript this is incomplete. For example in Figure 2B there are p-values indicated (asterisks), but in the legend these p-values, their actual value and the test used are not mentioned. It is also not clear what significant difference to which value was tested in 2B. Please fix this for all the other relevant panels.
3rd Revision -authors' response 07 August 2016
I sincerely apologize for not addressing the necessary points in the previous version.
We have now took care to address all the points that have been mentioned in your email.
The number of replicates are mentioned in the figure legend for Fig.4C /D, EV3B and EV4A/I.
For Fig.6D , the p-values are calculated and mentioned in the figure legend and the Fig.6D is modified according to that.
In Fig.4F , the quantification is from the particular blots shown in Fig.EV4O and we mentioned that in the figure legend.
Please find the attached the revised version of text and the new figure for Fig.6 (TIFF format) with this email.
Please let us know if we need to provide any further details.
Thank you for your patience. I am very pleased to accept your manuscript for publication in the next available issue of EMBO reports. Thank you for your contribution to our journal.
